Search clinical trials for: EGFR mutation-positive inoperable or recurrent NSCLC

Total 211810 results

Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Halozyme Therapeutics

Terminated

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC (PRIMAL)

Non-small Cell Lung Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC

Recurrent Non Small Cell Lung Cancer

United States, Singapore
Yonsei University

Unknown

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Completely Resected NSCLC With Common EGFR Mutations

Korea, Republic of
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.

Completed

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

Head and Neck Cancer

United States
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-Small Cell Lung Cancer | Brain Metastases
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
American College of Radiology Imaging Network
National Cancer Institute (NCI)

Terminated

FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy (ACRIN6678)

Lung Cancer

United States
Novartis Pharmaceuticals

Withdrawn

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma | Non-Small-Cell Lung Cancer
Eisai Co., Ltd.

Completed

Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.

Breast Cancer | HER2-negative Breast Cancer

Japan
SCRI Development Innovations, LLC
Achieve Life Sciences

Completed

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (Spruce)

Non Squamous Non Small Cell Lung Cancer

United States
Sun Yat-sen University

Unknown

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (SEQUENCE)

Non Small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, Taiwan, Singapore, Japan
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
M.D. Anderson Cancer Center
AstraZeneca; MedImmune LLC

Withdrawn

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma | Advanced Lung Cancer | Recurrent Nonsmall Cell Lung Cancer
David M. Jackman, MD
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital

Completed

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Non-small Cell Lung Cancer

United States
AstraZeneca

Terminated

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) (PANORAMA)

Carcinoma, Non-Small-Cell Lung

France, Spain, United Kingdom, China, Canada, Taiwan
Prof. Dr. Berthold Schalke
Crolll Gmbh

Completed

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Primary Inoperable Thymoma | Local Recurrent Thymoma

Germany
Incyte Corporation

Terminated

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
VA Office of Research and Development
National Cancer Institute (NCI); Jonsson Comprehensive Cancer Center

Terminated

A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer (VTNSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States
Peking University
Chinese PLA General Hospital

Unknown

Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma (NIEGA)

Stomach Neoplasms

China
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

Lung Cancer | Non Small Cell Lung Cancer

United States
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Masonic Cancer Center, University of Minnesota

Terminated

Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC

Lung Cancer

United States
iOMEDICO AG
Novartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische Onkologie

Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (IMPROVE)

Breast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of Breast

Germany
AHS Cancer Control Alberta

Completed

Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours

Lung Neoplasms | Lung Cancer

Canada
National Cancer Institute (NCI)

Completed

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Adenocarcinoma | Unresectable Pancreatic Carcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States, Canada
Centre Francois Baclesse
Hoffmann-La Roche; Groupe Français de Pneumo-Cancérologie

Terminated

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

NSCLC Patients With EGFR Activating Mutation

France
Ahmad Tarhini
Pfizer

Completed

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

Melanoma

United States
Bayer

Completed

A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (CAPTURE)

Hypertension, Pulmonary

Japan, Germany, Sweden, Colombia, Turkey, Belgium, Canada
AstraZeneca

Completed

Asia Pacific and Russia Diagnostic Study for EGFR Testing (IGNITE)

EGFR Mutation Status in aNSCLC Patients

Korea, Republic of, Russian Federation, Malaysia, China, Australia, Taiwan, Thailand, Indonesia, Singapore
Peking University

Completed

A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Gastric Cancer

China
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
Asbestos Diseases Research Foundation
EnGeneIC Limited

Completed

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Australia
National Cancer Institute (NCI)

Completed

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (MAESTRO HN)

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States, China
National Cancer Institute (NCI)

Completed

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

Stage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Completed

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Thoracic Neoplasms

China
GlaxoSmithKline

Terminated

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, Canada
National Cancer Institute (NCI)

Completed

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Thyroid Gland Medullary Carcinoma

United States
Jinming Yu
Roche Pharma AG

Unknown

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 (RECEL)

Non-small Cell Lung Cancer

China
EMD Serono

Completed

A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer

Ovarian Cancer

United States
Yonsei University

Withdrawn

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

NSCLC
Washington University School of Medicine

Terminated

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

Prostate Cancer | Metastatic Cancer

United States
Caicun Zhou

Unknown

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Pierre Fabre Medicament
Pierre Fabre Pharma GmbH

Completed

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

NSCLC

Germany
Genzyme, a Sanofi Company

Completed

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer (ZODIAC)

Lung Cancer | Non-small Cell Lung Cancer

Vietnam, United States, Brazil, France, Italy, Korea, Republic of, Mexico, Spain, Turkey, Germany, China, Japan, Netherlands, Argentina, Austria, Belgium, Canada, Portugal, Greece, India, Denmark, Malaysia, Indonesia, Thailand, Singapore
AstraZeneca

Completed

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France

Search clinical trials for: EGFR mutation-positive inoperable or recurrent NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations